Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | Zendy

Juan P. Frías | Zendy; Melanie J. Davies | Zendy; Julio Rosenstock | Zendy; Federico C. Pérez Manghi | Zendy; Laura Fernández Landó | Zendy; Brandon K. Bergman | Zendy; Bing Liu | Zendy; Xuewei Cui | Zendy; Katelyn Brown | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Author(s) -

Juan P. Frías,

Melanie J. Davies,

Julio Rosenstock,

Federico C. Pérez Manghi,

Laura Fernández Landó,

Brandon K. Bergman,

Bing Liu,

Xuewei Cui,

Katelyn Brown

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2107519

Subject(s) - semaglutide , agonist , glucagon like peptide 1 receptor , type 2 diabetes , medicine , receptor , endocrinology , diabetes mellitus , glucagon like peptide 1 , liraglutide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research